Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-up BiPar Seeks Fast Track In PARP Inhibition

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.

You may also be interested in...



Sanofi-Aventis Grabs Start-up BiPar, Reels In Promising PARP Inhibitor For Cancer

All-cash deal could be worth up to $500 million in upfront and milestone payments.

Sanofi-Aventis Grabs Start-up BiPar, Reels In Promising PARP Inhibitor For Cancer

All-cash deal could be worth up to $500 million in upfront and milestone payments.

Workforce Needs Top California Trade Group’s Policy Agenda

Meanwhile, bio industry looks to Obama for short-term financial relief amid economic crisis.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel